Supernus Pharmaceuticals completed a merger on November 2, 2026, and its common stock is being removed from public trading. The company asked Nasdaq to suspend trading in its shares before the market opened that day and to begin the process of delisting them.
- Trading and listing: Supernus common stock will no longer trade on Nasdaq or any other national securities exchange.
- End of public-company reporting: After the delisting takes effect, Supernus intends to seek deregistration of its shares and suspension of its ongoing public-company reporting obligations.
- Merger details: The announcement gives no information about the merger partner, transaction price, consideration or ownership arrangements.
What changes: Supernus shares will cease to be exchange-listed, and the company intends to end its public reporting obligations. The announcement does not specify what happens to shareholders’ holdings under the merger terms.